November 4, 2025
Currax Announces ObesityWeek® Data Showing that CONTRAVE® Helps Curb Cravings and Offers Marked Effectiveness in Certain Populations with Obesity
Read moreOctober 29, 2025
Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®
Read moreOctober 23, 2025
Currax Pharmaceuticals LLC to Provide CONTRAVE® at No Cost to Federal Employees During Government Shutdown
Read moreAugust 5, 2025
Currax Announces National Expansion of “Cravings Don’t Own Me” CTV Commercial, Along with Launch of New “Real Patients, Real Results” DTC Campaign
Read moreJuly 15, 2025
Currax Expands Access to FDA-Approved Obesity Treatment with Brand Name Contrave® with New Cash Price Available via GoodRx
Read moreMarch 20, 2025
Currax Secures Reliable and Consistent Supply of CONTRAVE®/MYSIMBA with FDA Approval for Second Manufacturing Site
Read moreMarch 11, 2025
Currax Pharmaceuticals: Peer-Reviewed Study in Obesity Pillars Further Substantiates Cardiovascular Safety Profile of CONTRAVE®/MYSIMBA®
Read moreFebruary 25, 2025
Currax Provides Update on Litigation Against Found Health Inc.
Read moreJanuary 10, 2025
Currax Announces Outstanding 2024 Financial and Operational Performance
Read moreJanuary 3, 2025